Kim M, Lee J-O, Koh J, Kim TM, Lee JY, Jeon YK, Keam B, Kim D-W, Lee JS, Heo DS. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Haematologica 2021;106(8):2277-2280; https://doi.org/10.3324/haematol.2021.278301.